614
Participants
Start Date
May 31, 2022
Primary Completion Date
May 29, 2026
Study Completion Date
June 30, 2026
RMC-6236
Oral Tablets
RECRUITING
Perlmutter Cancer Center at NYU Langone Health, New York
RECRUITING
Memorial Sloan-Kettering Cancer Center, New York
RECRUITING
Columbia University, New York
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
Next Oncology Virginia, Fairfax
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
Christ Hospital Cancer Center, Cincinnati
RECRUITING
Mary Crowley Cancer Research, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Next Oncology, San Antonio
RECRUITING
University of Texas at Austin, Austin
RECRUITING
Huntsman Cancer Institute, Salt Lake City
RECRUITING
UCLA, Santa Monica
RECRUITING
UC Irvine/Chao Family Comprehensive Cancer Center, Orange
RECRUITING
Dana Farber Cancer Institute, Boston
Revolution Medicines, Inc.
INDUSTRY